Vaxxinity announces first parkinson's disease patient dosed in part b of phase 1 clinical trial of ub-312

Dallas, jan. 12, 2022 (globe newswire) -- vaxxinity, inc. (nasdaq: vaxx), a u.s. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that the first patient with parkinson's disease (pd) has been dosed with ub-312 in part b of a double-blinded, placebo-controlled phase 1 clinical trial, following completion of part a of the phase 1 trial in healthy volunteers.
VAXX Ratings Summary
VAXX Quant Ranking